Cargando…

Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems

One of the characteristic features of aging is the progressive loss of muscle mass, a nosological syndrome called sarcopenia. It is also a pathologic risk factor for many clinically adverse outcomes in older adults. Therefore, delaying the loss of muscle mass, through either boosting muscle protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung Hoon, Jeon, Jun Hyoung, Lee, Min Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551806/
https://www.ncbi.nlm.nih.gov/pubmed/32859116
http://dx.doi.org/10.3390/nu12092597
_version_ 1783593259912658944
author Lee, Jung Hoon
Jeon, Jun Hyoung
Lee, Min Jae
author_facet Lee, Jung Hoon
Jeon, Jun Hyoung
Lee, Min Jae
author_sort Lee, Jung Hoon
collection PubMed
description One of the characteristic features of aging is the progressive loss of muscle mass, a nosological syndrome called sarcopenia. It is also a pathologic risk factor for many clinically adverse outcomes in older adults. Therefore, delaying the loss of muscle mass, through either boosting muscle protein synthesis or slowing down muscle protein degradation using nutritional supplements could be a compelling strategy to address the needs of the world’s aging population. Here, we review the recently identified properties of docosahexaenoic acid (DHA). It was shown to delay muscle wasting by stimulating intermediate oxidative stress and inhibiting proteasomal degradation of muscle proteins. Both the ubiquitin–proteasome and the autophagy–lysosome systems are modulated by DHA. Collectively, growing evidence indicates that DHA is a potent pharmacological agent that could improve muscle homeostasis. Better understanding of cellular proteolytic systems associated with sarcopenia will allow us to identify novel therapeutic interventions, such as omega-3 polyunsaturated fatty acids, to treat this disease.
format Online
Article
Text
id pubmed-7551806
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75518062020-10-14 Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems Lee, Jung Hoon Jeon, Jun Hyoung Lee, Min Jae Nutrients Review One of the characteristic features of aging is the progressive loss of muscle mass, a nosological syndrome called sarcopenia. It is also a pathologic risk factor for many clinically adverse outcomes in older adults. Therefore, delaying the loss of muscle mass, through either boosting muscle protein synthesis or slowing down muscle protein degradation using nutritional supplements could be a compelling strategy to address the needs of the world’s aging population. Here, we review the recently identified properties of docosahexaenoic acid (DHA). It was shown to delay muscle wasting by stimulating intermediate oxidative stress and inhibiting proteasomal degradation of muscle proteins. Both the ubiquitin–proteasome and the autophagy–lysosome systems are modulated by DHA. Collectively, growing evidence indicates that DHA is a potent pharmacological agent that could improve muscle homeostasis. Better understanding of cellular proteolytic systems associated with sarcopenia will allow us to identify novel therapeutic interventions, such as omega-3 polyunsaturated fatty acids, to treat this disease. MDPI 2020-08-26 /pmc/articles/PMC7551806/ /pubmed/32859116 http://dx.doi.org/10.3390/nu12092597 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lee, Jung Hoon
Jeon, Jun Hyoung
Lee, Min Jae
Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title_full Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title_fullStr Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title_full_unstemmed Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title_short Docosahexaenoic Acid, a Potential Treatment for Sarcopenia, Modulates the Ubiquitin–Proteasome and the Autophagy–Lysosome Systems
title_sort docosahexaenoic acid, a potential treatment for sarcopenia, modulates the ubiquitin–proteasome and the autophagy–lysosome systems
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551806/
https://www.ncbi.nlm.nih.gov/pubmed/32859116
http://dx.doi.org/10.3390/nu12092597
work_keys_str_mv AT leejunghoon docosahexaenoicacidapotentialtreatmentforsarcopeniamodulatestheubiquitinproteasomeandtheautophagylysosomesystems
AT jeonjunhyoung docosahexaenoicacidapotentialtreatmentforsarcopeniamodulatestheubiquitinproteasomeandtheautophagylysosomesystems
AT leeminjae docosahexaenoicacidapotentialtreatmentforsarcopeniamodulatestheubiquitinproteasomeandtheautophagylysosomesystems